We are excited to be exhibiting at BIO Int. Convention, June 16-19, 2025 in Boston, USA.
Visit our team at booth #2647 or schedule a meeting with us ahead of time via BIO’s 1:1 partnering system . Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,200 employees. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including, sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and, pharmaceutical product development
ReciBioPharm, a division of Recipharm, is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specializsed CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Led by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.